Stifel lowered the firm’s price target on Staar Surgical (STAA) to $19 from $28 and keeps a Hold rating on the shares. China refractive end market uncertainty seemingly persists, which may make it difficult for Staar to get back to normalized worldwide growth of at least high-single digits, which the firm believes is “what will help shares start to work again.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STAA:
- Staar Surgical Announces Chief Legal Officer Transition Plan
- Adobe downgraded, Palantir upgraded: Wall Street’s top analyst calls
- Staar Surgical initiated with a Neutral at Wedbush
- Staar Surgical Names Interim Co-CEOs Amid Leadership Transition
- Staar Surgical appoints COO Warren Foust, CFO Deborah Andrews as interim co-CEOs